|
| Status |
Public on Jan 30, 2017 |
| Title |
GHE0925 [expression] |
| Sample type |
RNA |
| |
|
| Source name |
DLBCL tumor biopsy
|
| Organism |
Homo sapiens |
| Characteristics |
ID: GHE0925A
diagnosis: DLBCL
age: 77
Sex: FEMALE
Stage: STAGE 3
treatment: R-CHOP21
ipi: 3
age_adjusted_ipi: 2
pfs_time: 68.13963039
cens_pfs: 1
os_time: 70.37371663
cens_os: 1
coo: ABC
|
| Extracted molecule |
total RNA |
| Extraction protocol |
Total RNA was isolated with the miRNeasy mini kit (Qiagen).
|
| Label |
biotin
|
| Label protocol |
Biotinylated cRNA was prepared by Expression Analysis, Inc. (Durham, NC).
|
| |
|
| Hybridization protocol |
Hybridization of cRNA on Affymetrix GeneChip Human Genome U133 Plus 2.0 arrays was performed by Expression Analysis, Inc.
|
| Scan protocol |
GeneChips were scanned with the GeneChip Scanner 3000 (Affymetrix). Images were analyzed with the Gene Chip® Operating Software (GCOS) 1.4
|
| Description |
Characteristics definitions:
ID: sample ID
AGE: age at diagnosis
SEX: male (M) or female (F)
TREATMENT: treatment line used
IPI: calculated IPI
Age_Adjusted_IPI: calculated age-adjusted IPI
PFS_TIME: duration of progression free survival (PFS) in months
CENS_PFS: coded as 0 if PFS event, 1 if not
OS_TIME: duration of overall survival (OS) in months
CENS_OS: coded as 0 if OS event, 1 if not
COO: cell of origin according to Affymetrix GeneChip arrays as described in methods
|
| Data processing |
The data were analyzed with GeneSpring software (Agilent Technologies) using default settings and the RMA normalization and summarization algorithm.
|
| |
|
| Submission date |
Sep 26, 2016 |
| Last update date |
Dec 06, 2019 |
| Contact name |
Sydney Dubois |
| Organization name |
Centre Henri Becquerel
|
| Lab |
INSERM U918
|
| Street address |
Rue d'Amiens
|
| City |
Rouen |
| ZIP/Postal code |
76000 |
| Country |
France |
| |
|
| Platform ID |
GPL570 |
| Series (2) |
| GSE87371 |
Expression data from Diffuse Large B Cell Lymphoma (DLBCL) patients |
| GSE136971 |
Expression data and Copy Number Variations from Diffuse Large B Cell Lymphoma (DLBCL) patients |
|
